CovidStanfordV1, Main, Exploration, bibRecord, 000654

Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?

Identifieur interne : 000654 ( Main/Exploration ); précédent : 000653; suivant : 000655

Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?

Auteurs : Roch Houot [États-Unis] ; Ronald Levy [États-Unis] ; Guillaume Cartron [France] ; Philippe Armand [États-Unis]

Source :

European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2020.

RBID : pubmed:32619884

Descripteurs français

KwdFr :
- Anticorps monoclonaux humanisés (effets indésirables), Antigènes CD20 (MeSH), Betacoronavirus (MeSH), Facteurs immunologiques (effets indésirables), Humains (MeSH), Infections à coronavirus (prévention et contrôle), Interactions médicamenteuses (MeSH), Pandémies (prévention et contrôle), Pneumopathie virale (prévention et contrôle), Rituximab (effets indésirables), Résultat thérapeutique (MeSH), Vaccins antiviraux (usage thérapeutique).
MESH :
- effets indésirables : Anticorps monoclonaux humanisés, Facteurs immunologiques, Rituximab.
- prévention et contrôle : Infections à coronavirus, Pandémies, Pneumopathie virale.
- usage thérapeutique : Vaccins antiviraux.
- Antigènes CD20, Betacoronavirus, Humains, Interactions médicamenteuses, Résultat thérapeutique.

English descriptors

KwdEn :
- Antibodies, Monoclonal, Humanized (adverse effects), Antigens, CD20 (MeSH), Betacoronavirus (MeSH), COVID-19 (MeSH), COVID-19 Vaccines (MeSH), Coronavirus Infections (prevention & control), Drug Interactions (MeSH), Humans (MeSH), Immunologic Factors (adverse effects), Pandemics (prevention & control), Pneumonia, Viral (prevention & control), Rituximab (adverse effects), SARS-CoV-2 (MeSH), Treatment Outcome (MeSH), Viral Vaccines (therapeutic use).
MESH :
- chemical , adverse effects : Antibodies, Monoclonal, Humanized, Immunologic Factors, Rituximab.
- chemical , therapeutic use : Viral Vaccines.
- chemical : Antigens, CD20, COVID-19 Vaccines.
- prevention & control : Coronavirus Infections, Pandemics, Pneumonia, Viral.
- Betacoronavirus, COVID-19, Drug Interactions, Humans, SARS-CoV-2, Treatment Outcome.

Abstract

A vaccine against SARS-CoV-2 might represent the most promising approach to halt durably the current COVID-19 pandemic. We believe that anti-CD20 therapy may jeopardise the efficacy of such a vaccine. This is regrettable because patients receiving anti-CD20 therapy (i.e. those with haematologic malignancies or autoimmune disorders) are particularly at risk of severe COVID-19 and, as such, are the most in need of a vaccine. Here, we review the reasons why anti-CD20 therapy may abrogate or diminish the efficacy of a vaccine against SARS-CoV-2 and we draw physicians' attention towards this potential risk so that it can be considered when evaluating the risk/benefit ratio of anti-CD20 therapy during the current pandemic.

DOI: 10.1016/j.ejca.2020.06.017
PubMed: 32619884
PubMed Central: PMC7315961

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000542
to stream Main, to step Curation: 000542

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?</title>
<author><name sortKey="Houot, Roch" sort="Houot, Roch" uniqKey="Houot R" first="Roch" last="Houot">Roch Houot</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Hematology, CHU Rennes, University of Rennes, INSERM U1236, Rennes, France; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: roch.houot@chu-rennes.fr.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Hematology, CHU Rennes, University of Rennes, INSERM U1236, Rennes, France; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Levy, Ronald" sort="Levy, Ronald" uniqKey="Levy R" first="Ronald" last="Levy">Ronald Levy</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, Stanford University School of Medicine, Stanford, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medical Oncology, Stanford University School of Medicine, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cartron, Guillaume" sort="Cartron, Guillaume" uniqKey="Cartron G" first="Guillaume" last="Cartron">Guillaume Cartron</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Hematology, CHU Montpellier University Hospitality, University of Montpellier, Institut de Génétique Moléculaire de Montpellier, CNRS UMR 5535, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Hematology, CHU Montpellier University Hospitality, University of Montpellier, Institut de Génétique Moléculaire de Montpellier, CNRS UMR 5535, Montpellier</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Armand, Philippe" sort="Armand, Philippe" uniqKey="Armand P" first="Philippe" last="Armand">Philippe Armand</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32619884</idno>
<idno type="pmid">32619884</idno>
<idno type="doi">10.1016/j.ejca.2020.06.017</idno>
<idno type="pmc">PMC7315961</idno>
<idno type="wicri:Area/Main/Corpus">000542</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000542</idno>
<idno type="wicri:Area/Main/Curation">000542</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000542</idno>
<idno type="wicri:Area/Main/Exploration">000542</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?</title>
<author><name sortKey="Houot, Roch" sort="Houot, Roch" uniqKey="Houot R" first="Roch" last="Houot">Roch Houot</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Hematology, CHU Rennes, University of Rennes, INSERM U1236, Rennes, France; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: roch.houot@chu-rennes.fr.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Hematology, CHU Rennes, University of Rennes, INSERM U1236, Rennes, France; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Levy, Ronald" sort="Levy, Ronald" uniqKey="Levy R" first="Ronald" last="Levy">Ronald Levy</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, Stanford University School of Medicine, Stanford, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medical Oncology, Stanford University School of Medicine, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cartron, Guillaume" sort="Cartron, Guillaume" uniqKey="Cartron G" first="Guillaume" last="Cartron">Guillaume Cartron</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Hematology, CHU Montpellier University Hospitality, University of Montpellier, Institut de Génétique Moléculaire de Montpellier, CNRS UMR 5535, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Hematology, CHU Montpellier University Hospitality, University of Montpellier, Institut de Génétique Moléculaire de Montpellier, CNRS UMR 5535, Montpellier</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Armand, Philippe" sort="Armand, Philippe" uniqKey="Armand P" first="Philippe" last="Armand">Philippe Armand</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">European journal of cancer (Oxford, England : 1990)</title>
<idno type="eISSN">1879-0852</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Humanized (adverse effects)</term>
<term>Antigens, CD20 (MeSH)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>COVID-19 Vaccines (MeSH)</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Drug Interactions (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Immunologic Factors (adverse effects)</term>
<term>Pandemics (prevention & control)</term>
<term>Pneumonia, Viral (prevention & control)</term>
<term>Rituximab (adverse effects)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
<term>Viral Vaccines (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux humanisés (effets indésirables)</term>
<term>Antigènes CD20 (MeSH)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Facteurs immunologiques (effets indésirables)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (prévention et contrôle)</term>
<term>Interactions médicamenteuses (MeSH)</term>
<term>Pandémies (prévention et contrôle)</term>
<term>Pneumopathie virale (prévention et contrôle)</term>
<term>Rituximab (effets indésirables)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Vaccins antiviraux (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term>
<term>Immunologic Factors</term>
<term>Rituximab</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Antigens, CD20</term>
<term>COVID-19 Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term>
<term>Facteurs immunologiques</term>
<term>Rituximab</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pandemics</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pandémies</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Drug Interactions</term>
<term>Humans</term>
<term>SARS-CoV-2</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Antigènes CD20</term>
<term>Betacoronavirus</term>
<term>Humains</term>
<term>Interactions médicamenteuses</term>
<term>Résultat thérapeutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A vaccine against SARS-CoV-2 might represent the most promising approach to halt durably the current COVID-19 pandemic. We believe that anti-CD20 therapy may jeopardise the efficacy of such a vaccine. This is regrettable because patients receiving anti-CD20 therapy (i.e. those with haematologic malignancies or autoimmune disorders) are particularly at risk of severe COVID-19 and, as such, are the most in need of a vaccine. Here, we review the reasons why anti-CD20 therapy may abrogate or diminish the efficacy of a vaccine against SARS-CoV-2 and we draw physicians' attention towards this potential risk so that it can be considered when evaluating the risk/benefit ratio of anti-CD20 therapy during the current pandemic.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32619884</PMID>
<DateCompleted><Year>2020</Year>
<Month>08</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0852</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>136</Volume>
<PubDate><Year>2020</Year>
<Month>09</Month>
</PubDate>
</JournalIssue>
<Title>European journal of cancer (Oxford, England : 1990)</Title>
<ISOAbbreviation>Eur J Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?</ArticleTitle>
<Pagination><MedlinePgn>4-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0959-8049(20)30350-6</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2020.06.017</ELocationID>
<Abstract><AbstractText>A vaccine against SARS-CoV-2 might represent the most promising approach to halt durably the current COVID-19 pandemic. We believe that anti-CD20 therapy may jeopardise the efficacy of such a vaccine. This is regrettable because patients receiving anti-CD20 therapy (i.e. those with haematologic malignancies or autoimmune disorders) are particularly at risk of severe COVID-19 and, as such, are the most in need of a vaccine. Here, we review the reasons why anti-CD20 therapy may abrogate or diminish the efficacy of a vaccine against SARS-CoV-2 and we draw physicians' attention towards this potential risk so that it can be considered when evaluating the risk/benefit ratio of anti-CD20 therapy during the current pandemic.</AbstractText>
<CopyrightInformation>Copyright © 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Houot</LastName>
<ForeName>Roch</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Hematology, CHU Rennes, University of Rennes, INSERM U1236, Rennes, France; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: roch.houot@chu-rennes.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Levy</LastName>
<ForeName>Ronald</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cartron</LastName>
<ForeName>Guillaume</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Department of Hematology, CHU Montpellier University Hospitality, University of Montpellier, Institut de Génétique Moléculaire de Montpellier, CNRS UMR 5535, Montpellier, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Armand</LastName>
<ForeName>Philippe</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>06</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Eur J Cancer</MedlineTA>
<NlmUniqueID>9005373</NlmUniqueID>
<ISSNLinking>0959-8049</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018951">Antigens, CD20</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber>
<NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>A10SJL62JY</RegistryNumber>
<NameOfSubstance UI="C533411">ocrelizumab</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>M95KG522R0</RegistryNumber>
<NameOfSubstance UI="C527517">ofatumumab</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>O43472U9X8</RegistryNumber>
<NameOfSubstance UI="C543332">obinutuzumab</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018951" MajorTopicYN="Y">Antigens, CD20</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Anti-CD20 antibody</Keyword>
<Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">Rituximab</Keyword>
<Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="Y">Vaccine</Keyword>
</KeywordList>
<CoiStatement>Conflict of interest statement R.H. reports receiving honoraria from Bristol-Myers Squibb, MSD, Gilead, Kite, Roche, Novartis, Janssen, and Celgene. R.L. reports receiving honoraria from Apexigen, Beigene, Forty-Seven, Teneobio, Sutro, Checkmate, Nurix, Dragonfly, Quadriga, GigaGen, Abpro, Spolight, Xcella, Immunoscore, and Walking Fish. G.C. reports receiving honoraria from Roche, Celgene, Abbvie, Sanofi, Gilead, and Janssen. P.A. reports receiving honoraria from Merck, BMS, Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics, Celgene, Morphosys, Daiichi Sankyo, Miltenyi, Tessa, GenMab, C4, Enterome; has received research funding from Genentech, Merck, BMS, Affimed, Adaptive, Roche, Tensha, and IGM.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>06</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>06</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>7</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>8</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>7</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32619884</ArticleId>
<ArticleId IdType="pii">S0959-8049(20)30350-6</ArticleId>
<ArticleId IdType="doi">10.1016/j.ejca.2020.06.017</ArticleId>
<ArticleId IdType="pmc">PMC7315961</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Clin Immunol. 2013 Feb;33(2):388-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23064976</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Neurol. 2013 Jun;20(6):975-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23521577</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Cancer. 2020 Jul;133:29-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32434108</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 28;323(16):1582-1589</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32219428</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2016 Sep;15(9):1123-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26985862</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Discov. 2020 Jul;10(7):935-941</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32357994</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Exp Hematop. 2009 May;49(1):9-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19474512</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2013 Sep 12;122(11):1946-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23851398</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 May 29;368(6494):948-950</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32393526</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2011 May 15;186(10):6044-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21498665</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2002 Sep 15;100(6):2257-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12200395</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Oncol. 1998 Aug;16(8):2825-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9704735</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Dis Ther. 2020 Apr 23;:1-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32328406</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Aug 14;369(6505):806-811</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32434945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Aug 14;369(6505):812-817</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32434946</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Aug 4;324(5):460-470</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32492084</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 2010 Jan;62(1):64-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20039397</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2011 Dec 22;118(26):6769-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22058114</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
<li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Languedoc-Roussillon</li>
<li>Massachusetts</li>
<li>Occitanie (région administrative)</li>
</region>
<settlement><li>Montpellier</li>
</settlement>
</list>
<tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Houot, Roch" sort="Houot, Roch" uniqKey="Houot R" first="Roch" last="Houot">Roch Houot</name>
</region>
<name sortKey="Armand, Philippe" sort="Armand, Philippe" uniqKey="Armand P" first="Philippe" last="Armand">Philippe Armand</name>
<name sortKey="Levy, Ronald" sort="Levy, Ronald" uniqKey="Levy R" first="Ronald" last="Levy">Ronald Levy</name>
</country>
<country name="France"><region name="Occitanie (région administrative)"><name sortKey="Cartron, Guillaume" sort="Cartron, Guillaume" uniqKey="Cartron G" first="Guillaume" last="Cartron">Guillaume Cartron</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000654 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000654 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidStanfordV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32619884
   |texte=   Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32619884" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidStanfordV1

This area was generated with Dilib version V0.6.38.
Data generation: Tue Feb 2 21:24:25 2021. Site generation: Tue Feb 2 21:26:08 2021

	Serveur d'exploration sur le Covid à Stanford
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le Covid à Stanford

Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?

Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki